SCHEMBL22499151

SCHEMBL22499151

C#Cc1cccc2c1cnn2C1CCCCO1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
CYP4F2 P78329 5/20 0.36
CYP4A11 Q02928 5/20 0.36
ATR Q13535 6/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
MAP3K5 Q99683 1/20 0.33
DGAT2 Q96PD7 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
PDE9A O76083 1/20 0.31
PRKCB P05771 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14722997 0.89 RXRA (0.41) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL22499396 0.85 ALDH1A1 (0.40) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL22499058 0.84 RXRA (0.41) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL806439 0.84 ATR (0.40) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL476884 0.83 RXRA (0.42) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL5019990 0.82 RXRA (0.39) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL22499056 0.81 RXRA (0.40) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL19915965 0.81 RXRA (0.40) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL30811724 0.81 RXRA (0.40) RXRARXRBRXRGALDH1A1LMNA
SCHEMBL156398 0.81 RXRA (0.42) RXRARXRBRXRGALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 US disclosed
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2025-04-17 US disclosed
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2025-01-14 US disclosed
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors STORM THERAPEUTICS LIMITED (GB) 2023-08-15 US disclosed
US-20230116403-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS EVOTEC INTERNATIONAL GMBH (DE) 2023-04-13 US disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 US disclosed
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2023-01-05 US disclosed
EP-4069694-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS Storm Therapeutics Ltd (GB) 2022-10-12 EP disclosed
CN-115151540-A Polyheterocyclic compounds as METTL3 inhibitors 风暴治疗有限公司 2022-10-04 CN disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 CN disclosed
WO-2021111124-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS STORM THERAPEUTICS LIMITED (GB) 2021-06-10 WO disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 RXRA 3680/4885RXRB 3424/4885RXRG 3482/4885
US-20250122195-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885
US-20230002378-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT RXRA 3396/4885RXRB 2830/4885RXRG 3139/4885
US-20230116403-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, DIMT1, TPMT RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885
US-11725010-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885
US-12195458-B2 Polyheterocyclic compounds as METTL3 inhibitors METTL3, DIMT1, TPMT RXRA 3584/4885RXRB 3449/4885RXRG 3445/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 RXRA 3680/4885RXRB 3424/4885RXRG 3482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.